302 results about "Analgesics drugs" patented technology

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

Disclosed is drug delivery for facilitating medical and/or procedures that are performed without “general anesthesia,” which is also described in the specification as the state of patient “unconsciousness” resulting from a drug administered by an anesthetist or anesthesiologist. Mixtures of sedative and analgesic drugs are adapted for safe and effective administration by devices to provide and maintain drug infusions that do not push the patient into unconsciousness and/or general anesthesia. Drug delivery devices are also disclosed that include the use of stored parameters and/or values that correlate to drug mixture delivery during a procedure, and a patient health monitor to measure and send signals regarding a patient health condition to a processor.

The invention discloses a medical suture that contains an analgesic drug which can slowly release in a body. The suture is combined with the analgesic drug. The medicine administration is simultaneously accomplished during suture, and the medicine is slowly released from the suture, thereby achieving the long term acesodyne effect on the sutured part. Due to the partial medicine administration, the medicine dosage is greatly reduced compared with the whole body medicine administration, and the side effect on the whole body is remarkably reduced while the partial effective pain stop is achieved.

The present invention includes systems and methods for decreasing the pain and discomfort commonly associated with endoscopic procedures, where such procedures may be performed with lower dosage levels of sedative and analgesic drugs. The invention includes use of an anesthetic collar coupled to an endoscope with a flexible shaft. The anesthetic collar allows lubricants, local anesthetics, dyes, and/or other desirable fluids to be passed through the existing lumen of the flexible shaft into an annulus, where the fluid may be distributed through expulsion pores into the gastrointestinal tract. Utilizing the existing lumens found in endoscopes, the present invention allows those fluids that may reduce the pain and discomfort associated with endoscopies such as, for example, local anesthetics and lubricants, to be distributed in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, where such fluids may reduce the drug level requirements for sedative and analgesic agents. Alternatively, the endoscope may be redesigned for streamlined integration with the anesthetic collar or to accomplish the same function of distributing local anesthetics and lubricants, in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, The invention can also be used with endoscopes without existing lumens.

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The invention belongs to the field of pharmacy, and mainly relates to a composition of a compound sustained-release drug delivery system capable of alleviating pain for a long term and promoting woundhealing and application. The main drug of the system is a composition of a local analgesic drug and a non-steroidal anti-inflammatory drug, and further comprises a solvent and a corresponding sustained-release material. The main drug adopts a local analgesic drug and non-steroidal anti-inflammatory drug compound, the local analgesic drug can remedy the poor pain alleviating effect of the non-steroidal anti-inflammatory drug used alone, and can enhance the pain alleviating effect by reducing the pain sensitivity of an organism, inhibit inflammatory response and promote wound healing; and in addition, the combined use of the local analgesic drug and the non-steroidal anti-inflammatory drug can reduce the administration dosages of the local analgesic drug and the non-steroidal anti-inflammatory drug to reduce respective adverse reactions.

It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an UV absorbent therein, the dibenzoylmethane derivative can be prevented from crystallization and sedimentation due to an oily phase component contained therein, and the inherent effects of the nonsteroidal anti-inflammatory and analgesic drug can be fully exerted without showing skin irritation caused by the oily phase component, an emulsifier and a thickener. The above problem can be solved by providing an antiinflammatory and analgesic preparation for external use which comprises a base for external use containing an oily phase component, a nonsteroidal antiinflammatory and analgesic drug and a dibenzoylmethane derivative and in which the total amount of fatty acid esters in the oily phase component is at least thrice as much as the content of the dibenzoylmethane derivative.

The invention discloses medical composite chitosan gel containing analgesic drug. The medical composite chitosan gel is prepared from, by weight, 0.5-10 parts of chitosan high molecular materials, 0.5-7 parts of analgesic drug, 0-10 parts of thickening agent, 1-25 parts of moistening agent and 48-98 parts of purified water. The medical composite chitosan gel containing the analgesic drug can effectively keep the wet environment for a wound and relieve wound pain; according to the dressing, the chitosan high molecular materials are used as a matrix, the analgesic drug is adopted in an assisted mode, the advantages of moisture absorption, moisturizing, bacteriostasis, hemostasis and the like and the effect of analgesia of the analgesic drug are combined, and the gel with excellent performance is prepared.

The invention synthesizes four novel endomorphin-1 analogs, and belongs to the technical field of biochemistry. The endomorphin-1 analogs are prepared by performing N-end guanidyl formation at the first-position Tyr of endomorphin-1, replacing the second-position Pro by D-Ala, replacing the third-position Trp by Gly, and replacing the fourth-position Phe by Trp or performing para-position chlorination and fluorination modification or no modification on a benzene ring of Phe. The synthesized endomorphin-1 analogs are subjected to a series of physiological and pharmacological activity identification such as radio-ligand receptor binding assays, isolated organ bioactivity identification experiments, isolated enzymolysis stability experiments, analgesic tests with water bath and medicine tolerance experiments, show high affinity activity, high enzymolysis stability and high analgesic activity, and hardly cause tolerance. Therefore, the four novel endomorphin-1 analogs can be used for preparing clinical analgesic medicines.

The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.

The invention discloses a preparation method of a polyurethane and sericin medical composite film with water absorption and moisture permeability. The steps are as follows: (1) preparation of polyurethane solution; (2) preparation of sericin suspension; (3) configuration of aliphatic polyurethane and sericin blend solution; (4) pouring membrane-forming liquid into glassine On the paper, the smear stick is evenly applied, and two methods of dry film formation and wet film formation are used to make a uniform film. Using sericin as the filling material, introducing sericin particles into the matrix not only forms micropores around the sericin particles, but also sericin contains a variety of amino acids with polar groups, and its good hydrophilicity provides a bridge for water transfer , so that the prepared film has good water absorption and moisture permeability. Bioactive ingredients can be loaded during the preparation process, and the bioactive ingredients can include various antibacterial, hemostatic, anti-inflammatory, analgesic drugs and/or growth factors and other active ingredients required for treatment to promote wound healing.

The invention discloses analgesia pump control method, device and equipment capable of achieving intelligent infusion. The equipment comprises a processor, a motor drive module and an analgesia depth detection module and/or breathing frequency detection module and/or blood oxygen monitoring module. The analgesia depth detection module and/or breathing frequency detection module and/or blood oxygen monitoring module and the motor drive module are electrically connected with the processor. The processor is used for obtaining detection signals sent by the analgesia depth detection module and/or breathing frequency detection module and/or blood oxygen monitoring module, judging the obtained detection signals respectively and sending a control signal to the motor drive module if any one of the detection signals is abnormal so as to drive a motor to make a analgesia pump stop working or lower the infusion speed. The analgesia pump control method has the advantages that multiple kinds of detection are combined, side effects caused by unreasonable analgesic drug infusion are detected, an alarm is given out, and the analgesia infusion risk is avoided.

The invention discloses a design of a comprehensive extraction process for barberry plant resources. Berbamine hydrochloride, jatrorrhizine hydrochloride, palmatine hydrochloride and a muscle relaxant are synchronously, efficiently and comprehensively extracted while berberine hydrochloride is extracted, and berbamine is used as a raw material for synthesizing an analgesic drug. Therefore, the barberry plant resources are fully utilized, the added medicinal value is increased, and the comprehensive utilization rate of medicinal barberry is increased. For a traditional Chinese medicine, one medicinal part is often utilized only and other parts are discarded. Various components in the barberry are synchronously extracted and comprehensively utilized, so that the economic value of the barberry is greatly increased.

A system and method provides closed-loop sedation, anesthesia, or analgesia by monitoring EEG and automatically adjusting the delivery of sedative, anesthetic, and/or analgesic drugs to maintain that desired or predetermined level of cortical at all echelons of care. The system and method further monitor the subject's cortical activity to detect occurrence of burst suppression which can be indicative of unsafe depth of anesthesia or sedation. Further, the system and methods provide for alteration or cessation of the administration of anesthesia or sedation based on the occurrence of burst suppression to mitigate harm to the subject.

This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof.

The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for curing various oral diseases. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the maim active component and combined with the commonly-used filling agents in various pharmaceutical industries to be prepared into various dosage forms or as drugs, health care products, food additives and the like, and the mangostin can be internally and externally used for ulcerative stomatitis, pharyngitis and the like, and also can be used for preening and curing the oral diseases, for example, the benign and malignant tumors of oral cavity. The content of the mangostin is between 1.2 and 99.8 percent, can be separately used or used by matching other substances, and also can be used for preventing and curing the oral diseases of animals. The product overcomes the defects in the prior drug for curing the oral diseases, such as poor effect, irritability, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.

Disclosed is a method for extracting and purifying active constituents from honeysuckle (Lonicera japonica Thunb.) and its use. More particularly, this invention relates to an extraction and purification method of active constituents including sweroside from for honeysuckle stem (stem of honeysuckle where leaves are removed) by removing tannins, hardly soluble flavonoids, saponins, and the like. Thus obtained active constituents have better anti-inflammatory and analgesic effect, are safer and more stable than the conventional active constituents obtained from honeysuckle flower or honeysuckle leaves, and include sweroside which is an effective active ingredient of anti-inflammatory and analgesic drug.

The invention relates to a novel broad-spectrum anti-inflammation analgesic drug for external use. The invention discloses a main compound extracted from mangosteen:Garcinia mangostana, i.e. mangostin, the mangostin is taken as the main active component and can be externally used for curing and preventing various acute and chronic ophthalmology and otorhinolaryngology inflammation, trauma and other symptoms after matching proper solvent or other preparations, and has the actions of excellent anti-inflammation, swelling reducing, abirritation, rapid hemostasis, affected part healing and the like. The content of the mangostin is between 0.1 and 99.8 percent and can be separately used or used by being matched with other substances, and the product overcomes the defects in the prior drug for curing the diseases, such as poor effect, high recurrence rate, side-effect and the like, and is the efficient and broad-spectrum new drug with anti-inflammation, rapid abirritation, non-toxicity, no side-effect and enhanced immunity.

A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).